These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19540293)

  • 1. Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design.
    Wei J; Li H; Qu W; Gao Q
    Neurochem Int; 2009 Dec; 55(7):637-42. PubMed ID: 19540293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
    Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
    Tafi A; Bernardini C; Botta M; Corelli F; Andreini M; Martinelli A; Ortore G; Baraldi PG; Fruttarolo F; Borea PA; Tuccinardi T
    J Med Chem; 2006 Jul; 49(14):4085-97. PubMed ID: 16821770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
    Jain V; Saravanan P; Arvind A; Mohan CG
    Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
    Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
    ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
    Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
    ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
    Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
    J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
    Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
    J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A(3) adenosine receptor antagonists.
    Moro S; Bacilieri M; Cacciari B; Spalluto G
    J Med Chem; 2005 Sep; 48(18):5698-704. PubMed ID: 16134938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
    J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.
    Cosimelli B; Greco G; Ehlardo M; Novellino E; Da Settimo F; Taliani S; La Motta C; Bellandi M; Tuccinardi T; Martinelli A; Ciampi O; Trincavelli ML; Martini C
    J Med Chem; 2008 Mar; 51(6):1764-70. PubMed ID: 18269230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations in compound database preparation--"hidden" impact on virtual screening results.
    Knox AJ; Meegan MJ; Carta G; Lloyd DG
    J Chem Inf Model; 2005; 45(6):1908-19. PubMed ID: 16309298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
    Morizzo E; Capelli F; Lenzi O; Catarzi D; Varano F; Filacchioni G; Vincenzi F; Varani K; Borea PA; Colotta V; Moro S
    J Med Chem; 2007 Dec; 50(26):6596-606. PubMed ID: 18047262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
    Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
    Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D pharmacophore based virtual screening of A 2A adenosine receptor antagonists.
    Wei J; Qu W; Ye Y; Gao Q
    Protein Pept Lett; 2010 Mar; 17(3):332-9. PubMed ID: 20236086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist.
    Moro S; Bacilieri M; Cacciari B; Bolcato C; Cusan C; Pastorin G; Klotz KN; Spalluto G
    Bioorg Med Chem; 2006 Jul; 14(14):4923-32. PubMed ID: 16564691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors.
    Bharatham K; Bharatham N; Park KH; Lee KW
    J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
    Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
    J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists.
    Poli D; Catarzi D; Colotta V; Varano F; Filacchioni G; Daniele S; Trincavelli L; Martini C; Paoletta S; Moro S
    J Med Chem; 2011 Apr; 54(7):2102-13. PubMed ID: 21401121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.